Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenVec's novel adenovector vaccine technology has received a boost with a $430,000 grant from the National Institute of Allergy and Infectious Diseases Biodefense Program.
Subscribe to our email newsletter
The new studies of this technology will incorporate influenza genes to assess their improved immunity against influenza and other diseases.
“While our initial development efforts will focus on an influenza vaccine, we will also be researching applications of this promising technology for a variety of other biodefense and disease prevention applications,” said Richter King senior vice president of research at GenVec.
GenVec has several adenovector based vaccines currently in development against a variety of diseases, including HIV, malaria, pandemic flu and foot and mouth disease.